62.51 USD
↘ 3.28 (4.99%)AT CLOSE (11:59 AM EDT)
Travere Therapeutics, Inc. Common Stock
TVTXNASDAQ • USD
62.67
↗ 0.16 (0.26%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
62.67
↗ 0.16 (0.26%)
Market: CLOSED
Travere Therapeutics, Inc. Common Stock (TVTX) trades at $62.53 per share. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, TVTX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Sep 15, 2026.
Open?$65.31
High?$65.32
Low?$61.40
Prev. Close?$65.79
Volume?2.1M
Avg. Volume?1.5M
VWAP?$62.24
Rel. Volume?1.36x
Bid / Ask
Bid?$61.24 × 1.0K
Ask?$64.10 × 200
Spread?$2.86
Midpoint?$62.67
Valuation & Ratios
Market Cap?5.9B
Shares Out?94.3M
Float?88.9M
Float %?95.6%
P/E Ratio?N/A
P/B Ratio?240.28
EPS?-$0.46
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Themes
Address
3611 VALLEY CENTRE DR
SAN DIEGO, CA 92130
Phone: 888-969-7879
SAN DIEGO, CA 92130
Phone: 888-969-7879
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?75
Momentum?57
Short Sent.?34
Piotroski F-Score?3/9Weak
Altman Z-Score?3.13Safe
Confidence?66%Moderate
Short InterestHigh
Short % of Float?13.50%High
Short Interest?12.0M
Days to Cover?9.6
Free Float88.9M
Avg Daily Volume1.3M
Settlement Date2026-08-31
Financial Health
Current Ratio?4.05Strong
Quick Ratio?3.99Strong
Cash Ratio?0.77Adequate
Debt/Equity?24.58High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?240.28HIGH▾
Peers100
S&P3
P/S?9.96HIGH▾
Peers100
S&P8
P/FCF?63.7PRICEY▾
Peers100
S&P6
EV/EBITDA?278.3HIGH▾
Peers100
S&P3
EV/Sales?10.78HIGH▾
Peers100
S&P9
Returns & Efficiency
ROE?-177.2%WEAK▾
S&P3
ROA?-5.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$92.5M
Enterprise Value?$6.4B
Fundamentals ratios updated end of day